<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Occup Environ Med</journal-id><journal-id journal-id-type="iso-abbrev">J Occup Environ Med</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of occupational and environmental medicine</journal-title></journal-title-group><issn pub-type="ppub">1076-2752</issn><issn pub-type="epub">1536-5948</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10922134</article-id><article-id pub-id-type="pmcid-ver">PMC10922134.319</article-id><article-id pub-id-type="pmcaid">10922134</article-id><article-id pub-id-type="pmcaiid">10922134</article-id><article-id pub-id-type="manuscript-id">NIHMS1948569</article-id><article-id pub-id-type="pmid">38151973</article-id><article-id pub-id-type="doi">10.1097/JOM.0000000000003029</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1948569</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1948569</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Productivity Loss Among Opioid and Benzodiazepine Users in the United States: A Medical Expenditure Panel Survey from 2010&#8211;2019</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6017-7500</contrib-id><name name-style="western"><surname>Thornton</surname><given-names initials="JD">J. Douglas</given-names></name><degrees>PharmD, PhD</degrees><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9795-8837</contrib-id><name name-style="western"><surname>Varisco</surname><given-names initials="T">Tyler</given-names></name><degrees>PharmD, PhD</degrees><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9028-3371</contrib-id><name name-style="western"><surname>Prachet</surname><given-names initials="B">Bhatt</given-names></name><degrees>M. Economics</degrees><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5775-5637</contrib-id><name name-style="western"><surname>Olateju</surname><given-names initials="O">Olajumoke</given-names></name><degrees>PharmD</degrees><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8497-8051</contrib-id><name name-style="western"><surname>Shrestha</surname><given-names initials="M">Mina</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5680-3134</contrib-id><name name-style="western"><surname>Shen</surname><given-names initials="C">Chan</given-names></name><degrees>PhD</degrees><xref rid="A3" ref-type="aff">c</xref></contrib></contrib-group><aff id="A1"><label>a</label>Prescription Drug Misuse Education and Research Center, College of Pharmacy, University of Houston, Houston, Texas, USA</aff><aff id="A2"><label>b</label>Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, Texas, USA</aff><aff id="A3"><label>c</label>Division of Outcomes Research and Quality, College of Medicine, Pennsylvania State University, Hershey, PA, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1"><underline>Specific Author contributions:</underline> DT, TV and CS conceptualized the study and finalized the analytical method. DT and TV analyzed and interpreted the MEPS data. DT, TV, OO, PB and MS drafted the manuscript. DT, TV, CS and MS critically reviewed the manuscript. All authors approved the final version of the manuscript.</p></fn><corresp id="CR1"><label>*</label>Corresponding Author: James Douglas Thornton; University of Houston College of Pharmacy, 4349 MLK Blvd, Houston, TX 77204-5000; Phone: 713-743-7358; <email>jdthornt@central.uh.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P29"><underline>Conflict of Interest</underline>: Dr. Thornton is currently a consultant for the Plaintiff&#8217;s Steering Committee for Opioid Litigation and a member of the Texas Opioid Abatement Settlement Council for the State of Texas. Dr. Varisco is a paid consultant for HEALIX Infusion Therapy. All other authors declare no conflicting interest.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>14</day><month>12</month><year>2023</year></pub-date><volume>66</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">457420</issue-id><fpage>226</fpage><lpage>233</lpage><pub-history><event event-type="nihms-submitted"><date><day>22</day><month>12</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-01 00:25:24.073"><day>01</day><month>03</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1948569.pdf"/><abstract id="ABS1"><sec id="S1"><title>Objective:</title><p id="P2">To estimate the association between productivity losses and the use of prescription opioids and benzodiazepines among employed US adults with painful conditions.</p></sec><sec id="S2"><title>Methods:</title><p id="P3">Using Medical Expenditures Panel Survey (2010&#8211;2019), we employed two-part (logistic regression and generalized linear model with zero-truncated negative binomial link) model to compare missed workdays due to illness or injury among employed adults with a painful condition.</p></sec><sec id="S3"><title>Results:</title><p id="P4">Of the eligible sample of 57,413 working US individuals, 14.65% were prescription opioid users, 2.95% were benzodiazepine users, and 1.59% were both opioid and benzodiazepine users. The predicted missed workdays were 5.75 (95%CL:5.58&#8211;5.92) days for benzodiazepine users, 13.06 (95%CL:12.88&#8211;13.23) days among opioid users, and 15.18 (95%CL:14.46&#8211;15.90) days for opioid and benzodiazepine concomitant users.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P5">Concomitant use of prescription opioids and benzodiazepines was significantly associated with having more missed workdays among employed adults with documented painful conditions.</p></sec></abstract><kwd-group><kwd>Opioids</kwd><kwd>Benzodiazepine</kwd><kwd>Productivity Loss</kwd><kwd>Absenteeism</kwd><kwd>MEPS</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>